why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat

Course: Hypotony Maculopathy Associated With Extruded Fluocinolone Acetonide Intravitreal Implant

CME Credits: 1.00

Released: 2023-08-17

A patient in their late sixties with advanced and active birdshot chorioretinopathy who underwent placement of a fluocinolone acetonide, 0.59 mg, intravitreal implant (Retisert; Bausch and Lomb) in their right eye 9 years ago and was receiving prednisone, mycophenolate mofetil, and infliximab-dyyb treatment presented with painless, decreased vision in the right eye. They denied any history of trauma or other ocular symptoms. Best-corrected visual acuity (VA) was 20/500 OD and 20/20 OS, and intraocular pressure (IOP) was 2 mm Hg and 14 mm Hg in the right and left eye, respectively. Examination revealed extrusion of the fluocinolone acetonide intravitreal implant (, A), 2+ anterior-chamber cell, 1+ vitreous cell, and diffuse chorioretinal folds (, B). The patient underwent pars plana vitrectomy with explantation of the implant. Two months later, VA with pinhole improved to 20/50 OD, IOP increased to 11 mm Hg, the anterior-segment and vitreous inflammation had resolved, and chorioretinal folds improved. This case highlights the fact that spontaneous fluocinolone acetonide intravitreal implant extrusion can rarely occur.


To identify the key insights or developments described in this article


View Full Course